Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: A methodological approach under serum-free culture conditions

Scandinavian Journal of Immunology

Volumn 62, Issue 1, 2005, Pages 75-85

  Kufner, S ^a   Zitzelsberger, H ^b   Kroell, T ^a   Pelka Fleischer, R ^a   Salem, A ^a   De Valle, F ^c   Schmid, C ^a   Schweiger, C ^c   Kolb, H J ^a   Schmetzer, H M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LEUKEMIA ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD AUTOTRANSFUSION; BONE MARROW CELL; CELL CULTURE; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOGENETICS; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKEMIA; MONONUCLEAR CELL; MYELODYSPLASIA; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADULT; AGED; ANTIGENS, CD; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CULTURE MEDIA, SERUM-FREE; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-4; LEUKEMIA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 22644446754     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01631.x     Document Type: Article

References (37)

1. Hirai H. Molecular pathogenesis of MDS. Int J Hematol 2002;2 (Suppl. 76):213-21.
2. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998;83:1104-15.
3. Maynadie M, Picard F, Husson B et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002;100:2349-56.
4. Aul C, Giagounidis A, Germing U, Ganser A. Myelodysplastic syndromes. Diagnosis and therapeutic strategies. Med Klin 2002;97:666-76.
5. Brossart P. Dendritic cells in vaccination therapies of malignant diseases. Transfus Apheresis Sci 2002;27:183-6.
6. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10-6.
7. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from the bench to bedside. Nat Med 2001;7:761-5.
8. Claxton DF, McMannis J, Champlin R, Choudhury A. Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress. Crit Rev Immunol 2001;21:147-55.
9. Galea-Lauri J. Immunological weapons against acute myeloid leukaemia. Immunology 2002;107:20-7.
10. Stripecke R, Levine AM, Pullarkat V, Cardoso AA. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia 2002;16:1974-83.
11. Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 2000;49:152-6.
12. Kufner S, Zitzelsberger H, Kroell T et al. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukemia: a methodological approach under serum-free culture conditions. Scand J Immunol 2005;62:86-98.
13. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
14. Stetler-Stevenson M, Arthur DC, Jabbour N et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001;98:979-87.
15. Hessel H, Mittermueller J, Zitzelsberger H, Weier HU, Bauchinger M. Combined immunophenotyping and FISH with sex chromosome-specific DNA probes for the detection of chimerism in epidermal Langerhans cells after sex-mismatched bone marrow transplantation. Histochem Cell Biol 1996;106:481-5.
16. Koehler T, Plettig R, Wetzstein W et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 2000;18:139-47.
17. Nguyen XD, Eichler H, Dugrillon A, Piechaczek C, Braun M, Klüter H. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. Journal of Immunological Methods 2003;9281:1-12.
18. Appelbaum FR. New targets for therapy in acute myeloid leukemia. Leukemia 2003;17:492-5.
19. Tsimberidou A, Estey E, Cortes J et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003;97:1481-7.
20. Bunjes D. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma 2002;43:2125-31.
21. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003;52:328-37.
22. Balaian L, Ball ED. Direct effect of bispecific anti-CD33 × anti-CD64 antibody on proliferation and signaling in myeloid cells. Leuk Res 2001;25:1115-25.
23. Song LP, Cheng JL, Wang XB et al. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003;35:503-10.
24. Van der Bruggen P, Traversari C, Chomez P. A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma. Science 1991;254:1643-7.
25. Brossart P, Grunebach F, Stuhler G et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 1998;92:4238-47.
26. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-47.
27. Harrison BD, Adams JA, Briggs M, Brereton ML, Liu Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by 'leukemic dendritic cells' derived from blasts cells in acute myeloid leukemia. Blood 2001;97:2764-71.
28. Santiago-Schwarz F, Coppock DL, Hindenburg AA, Kern J. Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. Blood 1994;84:3054-62.
29. Woiciechowsky A, Regn S, Kolb H-I, Roskrow M. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 2001;15:246-55.
30. Rigolin GM, Howard J, Buggins A et al. Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes. Br J Haematol 1999;107:844-50.
31. Sepp N, Zwierzina H, Smolle J, Schmalzl F, Fritsch P, Schuler G. Epidermal Langerhans cells in myelodysplastic syndromes are abnormal. J Invest Dermatol 1991;96:932-6.
32. Micheva I, Thanopoulou E, Michalopoulou S et al. Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome. Br J Haematol 2004;126:806-14.
33. Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2002;2:982-7.
34. Westermann J, Kopp J, van Lessen A et al. Dendritic cells vaccination in BCR/ABL-positive chronic myeloid leukemia - final results of a phase I/II ASH 2004, Abstract# 2934.
35. Caux C, Massacrier C, Vanbervliet B et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor α. II. Functional analysis. Blood 1997;4:1458-70.
36. Choudhury A, Liang JC, Thomas EK et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999;93:780-6.
37. Appelbaum FR. New targets for therapy in acute myeloid leukemia. Leukemia 2003;17:492-5.